A Phase 2, Open-Label, Multi-Center Study of Amuvatinib in Combination With Platinum-Etoposide Chemotherapy in Small Cell Lung Cancer Subjects Who Have Not Responded to Standard Treatment or Relapsed After Standard Treatment.

Trial Profile

A Phase 2, Open-Label, Multi-Center Study of Amuvatinib in Combination With Platinum-Etoposide Chemotherapy in Small Cell Lung Cancer Subjects Who Have Not Responded to Standard Treatment or Relapsed After Standard Treatment.

Discontinued
Phase of Trial: Phase II

Latest Information Update: 01 Nov 2013

At a glance

  • Drugs Amuvatinib (Primary)
  • Indications Small cell lung cancer
  • Focus Therapeutic Use
  • Acronyms ESCAPE
  • Sponsors Astex Pharmaceuticals
  • Most Recent Events

    • 21 Sep 2012 Primary endpoint 'Complete-clinical-response-rate' has not been met.
    • 21 Sep 2012 Status changed from active, no longer recruiting to discontinued.
    • 19 Sep 2012 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top